💊Baxdrostat, Blood Pressure, Breakthrough! New Hope for Uncontrolled Hypertension

🚨 New NEJM Study Alert! 🧬💊 Baxdrostat, a selective aldosterone synthase inhibitor, shows significant BP reduction in patients with resistant & uncontrolled hypertension despite RAAS blockade and diuretic therapy.   ✅ SBP ↓ ~9–10 mmHg at 12 weeks 🧂 Targets salt-retaining physiology ⚖️ Well-tolerated: early mild hyperkalemia & hyponatremia 🔁 Durable effect even after withdrawal   A promising step toward precision therapy in tough-to-treat hypertension! 📖 Read more: NEJM Aug 2025 | BaxHTN Trial #Hypertension #Cardiology #Baxdrostat #Aldosterone #RAAS #NEJM #PrecisionMedicine #ClinicalTrials